IM8 Lands $1 Billion Growth Deal with General Catalyst's Customer Value Fund

July 15, 2026 - 01:14

IM8, the premium supplement brand under Prenetics, has secured a massive $1 billion growth financing agreement from General Catalyst's Customer Value Fund (CVF). The deal marks a major milestone for the brand, which has been described as the fastest-growing premium supplement company ever recorded.

Since its launch, IM8 has delivered over 50 million servings to customers. The company now ships approximately 200,000 servings daily, with a new order placed every 27 seconds. The brand's rapid growth has prompted Prenetics to raise its full-year 2026 revenue guidance for IM8 to between $210 million and $220 million, up from the previous range of $190 million to $210 million.

Looking ahead, IM8 is expected to reach $300 million in annualized run-rate revenue by the end of 2026. The company projects full-year 2027 revenue of $400 million or more. A key factor driving this growth is the brand's efficient customer acquisition strategy, where every dollar invested in acquiring new customers generates strong returns.

The financing from General Catalyst's CVF will provide IM8 with the capital needed to scale operations, expand marketing efforts, and accelerate product development. The partnership signals strong investor confidence in the supplement brand's trajectory and its ability to capture a significant share of the premium wellness market.